TY - JOUR
T1 - The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy
AU - Di Biase, Luigi
AU - Auricchio, Angelo
AU - Sorgente, Antonio
AU - Civello, Kenneth
AU - Klersy, Catherine
AU - Faletra, Francesco
AU - Riedlbauchova, Lucie
AU - Patel, Dimpi
AU - Arruda, Mauricio
AU - Schweikert, Robert A.
AU - Martin, David O.
AU - Saliba, Walid I.
AU - Moccetti, Tiziano
AU - Wilkoff, Bruce L.
AU - Natale, Andrea
PY - 2008/10
Y1 - 2008/10
N2 - Aims: We assessed the relationship between cardiac resynchronization therapy (CRT)-induced reverse remodelling and mortality during a long-term follow-up in a prospective observational study. Methods and results: We analyzed data from a prospective registry including 398 consecutive patients who underwent CRT between September 1998 and September 2007. Left ventricular ejection fraction (LVEF) was assessed before CRT and in the period between 3 and 6 months following implant. All-cause mortality, urgent transplantation and implantation of left ventricular assist device were all considered relevant events. A total of 398 (179 non-ischaemic and 219 ischaemic) patients were analysed. Overall, the increase of LVEF was statistically significant and was computed with 7.0 points (95% CI 5.8-8.3, P <0.001). Non-ischaemic patients had a larger increase [9.2 points (95% CI 7.0-11.1), P <0.001] of their LVEF from baseline, when compared with the ischaemic group. The median duration of follow-up was 4.4 years. The cumulative incidence of all events at the end of the 96 months period of follow-up was 55% and it was 34% (95% CI 29-40) at 5 years. At the multivariable analysis of the event-free survival, aetiology lost its predictive value (HR 0.92, P = 0.47), while a change in LVEF ≥6 points still significantly decreased the risk of event during the follow-up (HR 0.30, P = 0.001). Conclusion: Reverse remodelling measured by LVEF after 3 months is a good predictor of long-term outcome. Patients with an increase in LVEF ≥6 points have an excellent event-free survival approaching 66% at 5 years of follow-up.
AB - Aims: We assessed the relationship between cardiac resynchronization therapy (CRT)-induced reverse remodelling and mortality during a long-term follow-up in a prospective observational study. Methods and results: We analyzed data from a prospective registry including 398 consecutive patients who underwent CRT between September 1998 and September 2007. Left ventricular ejection fraction (LVEF) was assessed before CRT and in the period between 3 and 6 months following implant. All-cause mortality, urgent transplantation and implantation of left ventricular assist device were all considered relevant events. A total of 398 (179 non-ischaemic and 219 ischaemic) patients were analysed. Overall, the increase of LVEF was statistically significant and was computed with 7.0 points (95% CI 5.8-8.3, P <0.001). Non-ischaemic patients had a larger increase [9.2 points (95% CI 7.0-11.1), P <0.001] of their LVEF from baseline, when compared with the ischaemic group. The median duration of follow-up was 4.4 years. The cumulative incidence of all events at the end of the 96 months period of follow-up was 55% and it was 34% (95% CI 29-40) at 5 years. At the multivariable analysis of the event-free survival, aetiology lost its predictive value (HR 0.92, P = 0.47), while a change in LVEF ≥6 points still significantly decreased the risk of event during the follow-up (HR 0.30, P = 0.001). Conclusion: Reverse remodelling measured by LVEF after 3 months is a good predictor of long-term outcome. Patients with an increase in LVEF ≥6 points have an excellent event-free survival approaching 66% at 5 years of follow-up.
KW - Cardiac resynchronization therapy
KW - Ejection fraction
KW - Heart failure
KW - Ischaemic and non-ischaemic aetiology
UR - http://www.scopus.com/inward/record.url?scp=54149092991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54149092991&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehn221
DO - 10.1093/eurheartj/ehn221
M3 - Article
C2 - 18515806
AN - SCOPUS:54149092991
SN - 0195-668X
VL - 29
SP - 2497
EP - 2505
JO - European Heart Journal
JF - European Heart Journal
IS - 20
ER -